Iradimed Stock Earnings Reports

IRADIMED reported its 17th consecutive quarter of record revenue with Q3 2025 revenue of $21.2 million, up 16% year-over-year. Gross margin remained strong at 78% and GAAP diluted EPS rose (~8% YoY). Growth was broad-based: MRI-compatible IV pumps (3860) revenue rose 20%, MRI patient monitors grew 16%, disposables were up 12%, domestic sales comprised ~85% of revenue. Management completed the move to a larger manufacturing facility and maintained margin targets despite the transition. The company received FDA clearance for the new 3870 MRI IV pump and plans a commercial rollout beginning with an initial 23-system deployment in December and a full U.S. sales-team launch after the January national sales meeting. Management expects bookings in early 2026 with revenue ramping in H2 2026 and sees a multi-year replacement opportunity: targeting adding ~1,000 pump channels/year from the existing >6,300 U.S. 5+-year-old 3860 channels, with a potential long-term domestic pump run-rate of ~2,000 channels/year and a pump revenue run-rate approaching $50 million. Management also projects company revenue could move into the $100M+ range when adding disposables, maintenance, international sales and MR monitoring. Guidance was raised: Q4 2025 revenue $21.4M–$22.4M; FY2025 revenue raised to $82.5M–$83.5M (up from prior $80M–$82.5M). GAAP and non-GAAP EPS guidance were both increased. The company declared a $0.17/share quarterly dividend payable Nov 25. Balance sheet/ cash: cash and equivalents of $56.5M at quarter end and strong operating cash flow (Q3 operating cash flow ~$7M), with completed facility construction (~$13.3M total). International regulatory clears (EU MDR, Japan) are targeted later (likely 2027) before broad 3870 international rollout. Management reiterated that forward-looking statements are subject to risks.